Intragastric Balloons: An Unfulfilled Promise
Authors: Gary M. Levine
Journal: Annals of Internal Medicine (1988)

Editorials1 September 1988Intragastric Balloons: An Unfulfilled PromiseGary M. Levine, MDGary M. Levine, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-5-354 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe use of an intragastric space-occupying device for treating obesity has been supported by circumstantial clinical evidence. First, the gastric bezoars that develop after stomach surgery have been associated with early satiety and weight loss (1). In addition, ingenious gastric stapling and gastroplasty procedures have been used to create tiny gastric pouches that severely limit meal size (2). Finally, in obese rats, gastric balloons have been shown to slow gastric emptying and reduce food intake (3).These physiologic findings have led to the development of intragastric balloons designed to produce afferent stimulation of the satiety centers (4-6). Implicit in this...References1. DeBakeyOschner MA. Bezoars and concretions: comprehensive review of literature with analysis of 303 collected cases and presentations of 8 additional cases. Surgery. 1938;4:934-8. Google Scholar2. Mason E. Vertical banded gastroplasty for obesity. Arch Surg. 1982;117:701-6. CrossrefMedlineGoogle Scholar3. GeliebterWestreichHashimGage ASSD. Gastric balloon reduces food intake and body weight in obese rats. Physiol Behav. 1987;39:399-402. CrossrefMedlineGoogle Scholar4. NiebenHarboe OH. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet 1982;1:198-9. CrossrefMedlineGoogle Scholar5. Percival W. The "balloon diet": a noninvasive treatment for morbid obesity: preliminary report on 108 patients. Can J Surg. 1984;27:135-6. MedlineGoogle Scholar6. GarrenGarrenGiordano MLF. The Garren gastric bubble: an Rx for the morbidly obese. Endosc Rev. 1984;2:57-60. Google Scholar7. WrightKrinskyFleemanTrujilloTeague RSCJE. Gastric emptying and obesity. Gastroenterology. 1984;84:747-51. CrossrefGoogle Scholar8. . Health implications of obesity. Ann Intern Med. 1985;103:147-51. LinkGoogle Scholar9. Spiro H. Bubble-mania. J Clin Gastroenterol. 1987;9:3. CrossrefMedlineGoogle Scholar10. Risks with gastric bubble. FDA Drug Bull. 1986;16(2):17. Google Scholar11. SchapiroBenjaminBlackburn MSG. Obesity and the gastric balloon: a comprehensive workshop. Gastrointest Endosc. 1987;33:323-7. CrossrefMedlineGoogle Scholar12. LindorHughesIlstrupJensen KRDM. Intragastric balloons in comparison with standard therapy for obesity: a randomized double blind trial. Mayo Clin Proc. 1987;62:992-6. CrossrefMedlineGoogle Scholar13. BenjaminMaherCiarleglio SKC. A double-blinded cross over study of the Garren-Edwards anti-obesity bubble [Abstract]. Gastrointest Endosc. 1987;33:168. Google Scholar14. MeshkinpourHsuFarivar HDS. The effect of gastric bubble as a weight reduction device: a controlled crossover study [Abstract]. Gastroenterology. 1987;92:1532. Google Scholar15. LevineGoldsteinLowe GMM. The gastric bubble—fad or fantastic [Abstract]. Gastroenterology. 1987;92:1505. Google Scholar16. HoganJohnstonLong RJB. The gastric bubble vs. sham endoscopy: a prospective randomized, controlled, double-blinded comparison as an adjunct to a standard weight loss program [Abstract]. Gastrointest Endosc. 1987;33:177. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Albert Einstein Medical Center Temple University School of Medicine Philadelphia, PA 19141 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byParastomal hernia incarceration due to migrated intragastric balloonEvolving Surgical Therapy for ObesityObesity surgery: Evidence-based guidelines of the European Association for Endoscopic Surgery (EAES)In Vitro Structure−Activity Relationship and in Vivo Studies for a Novel Class of Cyclooxygenase-2 Inhibitors: 5-Aryl-2,2-dialkyl-4-phenyl-3(2 H )furanone DerivativesThe EAES Clinical Practice Guidelines on Obesity Surgery (2005) 1 September 1988Volume 109, Issue 5Page: 354-356KeywordsEatingGastroenterology and hepatologyObesityOverweightStomachSurgeryWeight loss Issue Published: 1 September 1988 PDF downloadLoading ...